Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS2398 + Adebrelimab in Advanced Solid Tumors
NCT06439589Phase 2Recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Jun 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of HRS2398 in solid tumor (advanced stage), sponsored by Hengrui Therapeutics. Primary endpoints: Dose-Limiting Toxicity, Recommended Phase II Dose and 1 more. Started Jun 2024; status: recruiting.
02
Drugs
HRS2398
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06439589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06439589.